德斯控股(08437.HK)與廣東天伴大健康產業訂立戰略合作意向書
格隆匯9月10日丨德斯控股(08437.HK)公吿,於2021年9月10日,公司的全資附屬公司,德斯(深圳)企業有限公司與廣東天伴大健康產業有限公司("廣東天伴大")訂立並無法律約束力的戰略合作意向書。
根據戰略合作意向書,集團與廣東天伴大開展功能性飲料的銷售,並對廣東天伴大的上下游業務提供健康諮詢服務。董事會認為,藉着開展功能性飲料的銷售及對廣東天伴大的上下游業務提供健康諮詢服務,將可以加強並支持集團於中國的業務發展,並使集團的客户基礎及服務更多元化。因此,與廣東天伴大進行戰略合作符合公司及其股東的整體利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.